Intellia Therapeutics Inc buy Canaccord Genuity Group Inc.
Start price
13.04.23
/
50%
€33.50
Target price
13.04.24
€59.72
Performance (%)
-29.85%
End price
14.04.24
€23.50
Summary
This prediction ended on 14.04.24 with a price of €23.50. The prediction for Intellia Therapeutics Inc disappointed with a performance of -29.85%. Canaccord_Genuity_Gr has a follow-up prediction for Intellia Therapeutics Inc where he still thinks Intellia Therapeutics Inc is a Buy. Canaccord_Genuity_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | -0.404% | -0.404% | 69.185% |
| iShares Core DAX® | 0.751% | -8.496% | 2.575% |
| iShares Nasdaq 100 | -1.405% | -2.771% | 15.682% |
| iShares Nikkei 225® | 0.417% | -9.291% | 29.655% |
| iShares S&P 500 | -0.590% | -2.868% | 9.963% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $66.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by Canaccord_Genuity_Gr for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.99
03.03.26
03.03.26
€41.04
03.03.27
03.03.27
-7.51%
31.03.26
31.03.26
